I
ARQT icon

INVST’s Arcutis Biotherapeutics ARQT Stock Holding History

INVST’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,205
Closed -$829K – 347
2026
Q1 		$829K Buy
35,205
+4,698
+15% +$120K 0.09% 180
2025
Q4 		$886K Sell
30,507
-1,600
-5% -$41K 0.1% 170
2025
Q3 		$605K Buy
32,107
+2,030
+7% +$32K 0.07% 226
2025
Q2 		$422K Buy
30,077
+9,425
+46% +$132K 0.05% 239
2025
Q1 		$323K Buy
+20,652
New +$291K 0.04% 240

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

INVST's ARQT Position: Q2 2026 in Review

INVST sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 35,205 shares — an estimated $829K sold.

INVST first reported a position in ARQT in Q1 2025 and held it in 5 quarters. The position peaked at $886K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • INVST reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • INVST sold 35,205 Arcutis Biotherapeutics shares in Q2 2026, an estimated $829K.
  • INVST first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 5 quarters.
  • INVST's Arcutis Biotherapeutics position peaked at $886K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on INVST's 13F filing for Q2 2026, filed 14 Aug 2026.